First Tracks Biotherapeutics

Name

First Tracks Biotherapeutics

Legal name

First Tracks Biotherapeutics, Inc.

Website

https://firsttracksbio.com

Company type

Public

Founded year

2026

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Antibody therapeutics development
• Clinical-stage biotechnology
• Autoimmune disease treatment
• Inflammatory disease therapies
• Immunology drug development

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Product Revenue: Pre-revenue clinical-stage company with no commercialized products. Future revenue dependent on successful clinical development and commercialization of pipeline assets ANB033, rosnilimab, and ANB101.
2. Private Placement Funding: Company secured $145 million in private placement commitments prior to spin-off, with $80 million in gross proceeds going directly to the company at $13.81 per share. Represents capital financing, not operational revenue.

Go-to-market motion2 records

Marketing channels4 records

Core offering

First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The company's pipeline consists of three development-stage assets: ANB033 (anti-CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis), Rosnilimab (anti-PD-1 antibody with completed Phase 2b for rheumatoid arthritis), and ANB101 (BDCA2-modulating antibody in Phase 1a). The company targets upstream immune pathways to selectively modulate pathogenic immune cells while preserving immune homeostasis.

Product overview

First Tracks Biotherapeutics is a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The portfolio consists of three development-stage assets: ANB033 (a novel anti-CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis), rosnilimab (a first-in-class pathogenic T-cell depleter with completed Phase 2b for rheumatoid arthritis), and ANB101 (a BDCA2-modulating antibody in Phase 1a). The company operates with deep research expertise in immunology, targeting activated immune cells in both the periphery and affected tissues to modulate critical pathways regulating autoimmunity and inflammation.

Differentiator

Problem solved

Functional benefit

Products and services

• ANB033 A novel anti-CD122 antagonist antibody that targets the shared beta subunit of the IL-15 and IL-2 receptors, offering a dual-pathway approach to reducing pathogenic inflammation. Currently in Phase 1b trials for celiac disease and eosinophilic esophagitis. The product modulates proliferation and survival of CD8+, CD4+ T cells, NK cells, and ILC2s.
• Rosnilimab A first-in-class anti-PD-1 antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues while sparing naive T cells. The product aims to restore immune homeostasis without broad immune suppression and is currently being studied in rheumatoid arthritis with completed Phase 2b trials showing JAK-like efficacy through 6 months with no treatment-related serious adverse events across approximately 185 patient-years of exposure.
• ANB101 A BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs), inhibiting interferon secretion and downstream immune activation. The product is more potent than litifilimab with longer half-life and deeper, more durable PD effect on pDC depletion. Currently in Phase 1a trials, it is positioned as an upstream modulator of immune activity across autoimmune and inflammatory diseases.

Quantifiable outcome

• ANB033 Phase 1b topline data expected Q4 2026 for celiac disease and mid-2027 for eosinophilic esophagitis
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered supporting.

• Celiac Disease FoundationsupportingOthers · 20 April 2026Patient advocacy partnership supporting celiac disease community through patient engagement initiatives, community walks, and collaboration on patient-centered drug development approach.
• Beyond CeliacsupportingOthers · 20 April 2026Patient advocacy partnership working to elevate patient voices and strengthen connections that move meaningful therapies forward for celiac disease patients.
• Arthritis FoundationsupportingOthers · 20 April 2026Partnership with patient advocacy organization supporting arthritis community, aligning with rosnilimab development for rheumatoid arthritis.
• National Rheumatoid Arthritis Society (NRAS)supportingOthers · 20 April 2026UK-based patient organization partnership supporting rheumatoid arthritis patients and advocacy efforts.
• Association of European Coeliac Societies (AOECS)supportingOthers · 20 April 2026European patient advocacy partnership supporting celiac disease communities across Europe.
• American Partnership for Eosinophilic Disorders (APFED)supportingOthers · 20 April 2026Patient advocacy partnership supporting patients with eosinophilic disorders, aligning with ANB033 development for eosinophilic esophagitis.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing antibody therapeutics (e.g., sonelokimab targeting IL-17A/F/ALB) for autoimmune and inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis. Most comparable to First Tracks Bio as a similarly-stage, similarly-sized biotech focused on inflammation biologics with differentiated antibody designs.
• Arcutis Biotherapeutics: Dermatology-focused biotech with approved and clinical-stage antibody/biologic therapies for inflammatory skin conditions (e.g., ZORYVE for psoriasis/atopic dermatitis). Comparable to First Tracks Bio as a clinical-stage inflammation biotech targeting chronic immune-mediated diseases with biologics.
• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications, including autoimmune diseases. Comparable to First Tracks Bio as a clinical-stage immunology-focused biotech with novel mechanisms and multiple pipeline programs aimed at autoimmune disease.

Others

• AnaptysBio: Former parent company of First Tracks Bio, now operating as a royalty-focused entity after spinning off its biopharma pipeline in April 2026. Included as a related-party peer given shared antibody discovery heritage and historical pipeline continuity.

Broad incumbents

• Eli Lilly: Global biopharma with multiple autoimmune/inflammation products including Olumiant (JAK inhibitor for RA) and Taltz (IL-17 inhibitor). Lilly's JAK franchise is the benchmark First Tracks' rosnilimab aims to compete with, making Lilly a key comparable incumbent.
• AbbVie: Global biopharma with leading autoimmune franchises including Skyrizi, Rinvoq, and Humira across RA, psoriasis, IBD, and other indications. Comparable to First Tracks Bio as the dominant incumbent in the autoimmune/inflammation therapeutic area that First Tracks' pipeline aims to compete with.
• Bristol-Myers Squibb: Major biopharma with autoimmune/inflammation assets including Zeposia and Sotyktu (deucravacitinib) for ulcerative colitis, psoriasis, and other indications. Comparable to First Tracks Bio as an incumbent in the autoimmune space with competing oral and biologic therapies.
• Incyte Corporation: Commercial-stage biopharma with multiple approved immunology products (e.g., Opzelura for atopic dermatitis, Jakafi) and a pipeline spanning autoimmune/inflammatory disease. Comparable to First Tracks Bio as a major developer of immunology therapeutics, though Incyte is at commercial scale.

Emerging players

• Alumis: Clinical-stage immunology biotech developing tyrosine kinase inhibitors for autoimmune diseases including psoriasis and lupus. Comparable to First Tracks Bio as a clinical-stage immunology company targeting autoimmune and inflammatory disease with novel mechanisms.
• Cabaletta Bio: Clinical-stage biotech developing cell therapies for autoimmune diseases such as pemphigus, SLE, and myositis. Comparable to First Tracks Bio as a clinical-stage company focused on modulating pathogenic immune responses in autoimmune indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about First Tracks Biotherapeutics